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Background: Use of endothelin receptor antagonists (ERA), phosphodiesterase type-5 (PDE-5)
inhibitors and prostaglandin analogues has resulted in improved outcomes in idiopathic pulmo-
nary arterial hypertension (IPAH) and systemic sclerosis-associated PAH (SSc-PAH) patients.
However, patients often deteriorate on monotherapy. The objective of this study is to evaluate
the effect of dual therapy on outcomes in IPAH and SSc-PAH.
Methods: A systematic review of MEDLINE (1950e2011), EMBASE (1980e2011) and CINAHL
(inception-2011) was conducted to identify studies that evaluated the effect of any dual
combination of ERA, PDE-5 inhibitors or prostaglandin analogues on 6-min walk distance
(6MWD), functional class (FC), haemodynamics, quality-of-life (QoL) or time-to-clinical-
worsening in IPAH or SSc-PAH. A standardized form was used to abstract design, sample size,
aetiology, outcome and treatment effect.
Results: Twenty-six observational studies and 6 randomized trials were identified. Using
combination PDE-5 inhibitor and prostaglandin analogues, 6/7 studies reported improvement
in 6MWD, 6/8 studies reported improvement in FC, 6/6 studies reported improvement in hae-
modynamics and 1 trial demonstrated improvement in QoL and time-to-clinical-worsening.
Using combination ERA and prostaglandin analogues, 4/6 studies and 1 trial reported improve-
ment in 6MWD, 3/3 studies and 1 trial reported improvement in FC, 4/5 studies and 1 trial re-
ported improvement in PAP. Using combination ERA and PDE-5 inhibitor, 4/7 studies reported
an improvement in 6MWD, and 2/6 report improvement in FC.Rheumatology, Ground Floor, East Wing, Toronto Western Hospital, 399 Bathurst Street, Toronto,
6 603 6417; fax: þ1 416 603 4348.
hn.on.ca (S.R. Johnson).
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particularly those who are deteriorating on monotherapy. Research should focus on subsets
of patients to identify the optimal timing and combination of dual therapy.
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Pulmonary arterial hypertension (PAH) is a disease charac-
terized by elevated right heart pressure, which can lead to
progressive heart failure, difficulty breathing, decreased
exercise capacity, decreased quality of life, and untimely
death. Using historic data of untreated patients, Idiopathic-
PAH (IPAH) has a median survival of 2.8 years,1 and systemic
sclerosis (scleroderma)-associated PAH (SSc-PAH) has
a median survival of 1 year,2 making their prognosis
comparable to many cancers. Conventional treatments for
PAH include the use of anticoagulants, oxygen, diuretics,
and digoxin.3 Calcium channel blockers are only effective in
about 7% of patients with IPAH and even less effective in
other forms of PAH.4
The management of PAH has evolved over the last two
decades with the introduction of agents that target
different mechanisms in the pathogenic process.3 Prosta-
glandin analogues (epoprostenol, treprostinil, iloprost,
beraprost) replace endogenous prostacyclin that is under-
produced in PAH. They promote vasodilation and inhibit
vascular proliferation and platelet aggregation.5 Endothelin
receptor antagonists (ERA)(bosentan, ambrisentan, sitax-
sentan) block the action of endothelin-1, a potent vaso-
constrictor that also promotes vascular smooth muscle cell
proliferation.6 Phosphodiesterase-5 (PDE-5) inhibitors (sil-
denafil, tadalafil) increase the effect of nitric oxide (NO) by
inhibiting the breakdown of NO second messenger, cyclic
guanosine monophosphate. This results in pulmonary
vasodilation and inhibition of smooth muscle cell prolifer-
ation.7 The introduction of ERA,8e10 PDE-5 inhibitors11 and
prostaglandin analogues12e18 in the management of PAH
have demonstrated improvements in dyspnoea scores,
subjective and objective measures of function (6 min walk
test distance (6MWD), functional class), haemodynamics
and quality of life. However, these benefits are not sus-
tained.19 After achieving initial improvement, patients
often decline in all measures and still succumb to
a premature death.20 The optimal management of patients
deteriorating on monotherapy in not known.19 Additionally,
significant side effects and difficult drug administration are
associated with many of these medications.21 For these
reasons, many believe that dual combination therapy using
drugs with different mechanisms of action that may have
additive or synergistic effects is the next therapeutic
option.
Animal and acute haemodynamic study data suggest that
dual therapy with different combinations of these agents
may lead to improved outcomes. Combination beraprost
and sildenafil result in improved pulmonary haemodynamics
compared with each drug alone in a monocrotaline-induced
rat model.22 In a study of 8 IPAH patients receiving epo-
prostenol, the addition of sildenafil results in an additional10% reduction in mean pulmonary artery pressure (mPAP),
8% increase in cardiac output, and 24% reduction in
pulmonary vascular resistance (PVR).23 Combination bera-
prost and sildenafil result in acute improvements in mean
PAP and PVR compared to beraprost monotherapy.24 In 5
IPAH patients, the addition of iloprost to sildenafil results in
greater reduction in mPAP than monotherapy.25
Given these observations, we undertook a systematic
review of the literature to evaluate the evidence regarding
the effect of dual therapy on outcomes in IPAH and SSc-
PAH. Specifically we evaluated the effect of any dual
combination of ERA, PDE-5 inhibitor or prostaglandin
analogues on clinically relevant outcomes (6MWD, func-
tional class, haemodynamics, quality of life and time to
clinical worsening) in adult patients with IPAH or SSc-PAH.
Methods
Search strategy
MEDLINE (1950eApril 2011), EMBASE (1980eApril 2011) and
CINAHL (inception to week 9 2011) were searched using the
following keywords with mapping to subject heading:
(pulmonary hypertension or pulmonary heart disease) and
(prostacyclin or epoprostenol or treprostinil or iloprost or
beraprost or prostaglandin or prostanoid or cycloprostin or
Pgi2 or Pgx or U 53,217 or ciloprost or Ilomedin or Sh 401or
cotherix or Dolner or Procylin or Trk 100) or (endothelin
receptor or endothelin receptor antagonist or bosentan or
Tracleer or Ro 47 0203 or sitaxsentan or sitaxsentan or Tbc
11,251 or thelin or ambrisentan or Bsf 208,075 or letairis or
volibris or lu 208,075 or tbc 11,251 or darusentan or Hmr
4005 or Lu 127,043 or Lu 135,252 or uniprost or remodulin or
U62840 or Ut15 or 15AU81) or (phophodiesterase inhibitors
or antiphosphodiesterase or phosphodiesterase antagonist
or sildenafil citrate or sildenafil nitrate or Patrex or tada-
lafil or Uk 92,480 or Viagra or alfin or Andros or helping or
sidegra). Drug name synonyms were identified using the
National Institutes of Health database ChemIDplus. The
search was limited to humans and adults, but without
language restriction. Titles and abstracts were screened by
three independent reviewers (SKB, SRJ, JTG) to identify
studies for full review. Reviewers were blinded to the
names of authors, institutions and journals. The bibliogra-
phies of included studies and review articles were also
searched for relevant publications.
Inclusion and exclusion criteria
Eligible studies must 1) report original data, 2) include
human subjects, 3) include adult patients >16 years of age,
4) include patients with IPAH or SSc-PAH, 5) evaluate the
732 S.R. Johnson et al.use of any dual combination of prostaglandin analogues
(epoprostenol, treprostinil, iloprost, beraprost), ERA
(bosentan, sitaxsentan, ambrisentan), and PDE-5 inhibitors
(sildenafil, tadalafil), and 6) report 6MWD, functional class
(New York Heart Association (NYHA), World Health Organi-
zation (WHO)), haemodynamic parameters (PAP, PVR),
quality of life (using any measure of health related quality
of life) or time to clinical worsening as an outcome.
Patients could use other conventional PAH medications
including calcium channel blockers and anticoagulation.
Studies were ineligible if they were 1) a review article, 2)
non-human study, 3) included paediatric patients, 4)
included patients with other causes of PAH (e.g. HIV,
congenital cardiac disease etc), 5) reported only mono-
therapy or dual therapy with medications other that ERA,
PDE-5 inhibitors or prostaglandin analogues as the inter-
vention, or 6) only reported acute haemodynamic changes
as the outcome.Figure 1 Flow diagram of systematic review.Data abstraction
Data from the full text of the identified studies were
independently abstracted by 2 reviewers on a standardized
abstraction form. Discrepancies were resolved through
consensus or by recourse to a third investigator. The
following information was abstracted for each article, 1)
study design (randomized trial or observational study
(cohort study, case series or case report), 2) sample size, 3)
aetiology (IPAH or SSc-PAH), 4) intervention, 5) outcome
measure, 6) treatment effect and measure of association.
The source article was used to resolve discrepancies.Trial quality
The quality of randomized trials was evaluated using the
validated Jadad quality assessment index.26 The quality
score ranges from 0 to 5, with score less than 3 indicating
poor quality. Quality assessment was conducted by 2
independent assessors (JTG, SRJ), and disagreement was
resolved through consensus.Results
Search results
Systematic review of the literature identified 1143 poten-
tially relevant citations. Review of titles and abstracts
excluded 1084 citations, leaving 59 articles for review.
After review of the full article, 27 were excluded. Studies
were excluded if they did not evaluate the patient groups
of interest, did not report the interventions of interest, did
not report the outcome of interest, did not report specific
outcome data for the subjects or interventions of interest
or did not report original data. One study reported was
excluded as it reported patients on different combinations
of PH therapy as one group.27 Thirty-two studies were
identified for inclusion in this study. Fig. 1.Studies
Of the 32 articles, 26 articles were observational studies
and 6 were randomized controlled trials. Studies of dual
therapy combinations included PDE-5 inhibitors with pros-
taglandin analogues (n Z 13 studies),28e38 ERA with pros-
taglandin analogues (n Z 11 studies),38e48 and ERA with
PDE-5 inhibitors (n Z 10)49e57 noting 2 studies reported 2
combinations21,38). Summaries of the studies are reported
in Tables 1e3.
Combination PDE-5 inhibitor and prostaglandin
analogues
Seven of the 11 observational studies reported 6MWD as an
outcome, 6 of which reported a beneficial treatment effect
of dual therapy.32e36 Functional class was reported as an
outcome in 8 observational studies. Six studies reported
a beneficial effect20,28,31e33,55 and 1 study demonstrated
a trend towards improved functional class.30 Six studies
reported haemodynamics (PAP and/or PVR) as outcomes,
all of which demonstrated a beneficial effect with dual
therapy.20,28,29,31,33,36 None of the studies reported quality
of life as an outcome. Both randomized trials demonstrated
improvement in 6MWD,37,38 and one trial demonstrated
improvement in quality of life and time-to-clinical
worsening.37
Combination ERA and prostaglandin analogues
Four of the 6 observational studies reporting 6MWD as an
outcome describe a beneficial effect with dual
therapy.39,41,42,44 Of the 4 randomized trials reporting
6MWD, 1 reported improvement38 and 1 reported a trend
towards benefit47 with combination therapy. All 3 obser-
vational studies35,39,41,42 and 1 clinical trial47 demonstrated
a beneficial effect of dual therapy on functional class. Four
of 5 observational studies40,41,43,44 and 1 randomized trial
demonstrated a beneficial effect of dual therapy on PAP.47
One trial demonstrated a beneficial effect of combination
therapy on time to clinical worsening.47
Table 1 Summary of combination PDE-5 inhibitor and prostaglandin analogue studies.
Reference Combination Patients Outcome measure Evidence of benefit
Observational studies
Ghofrani 2003 Iloprost þ Sildenafil 9 IPAH 5
SSc-PAH
6MWD at 12 weeks: baseline 217  31 m, 12-week 346  26 m,
86 m (95% CI 30, 144 m) change, p Z 0.002
mPAP at 12 weeks:58.6  2.1 mmHg, 12-week 58.6  2.6 mmHg
Functional class: Class IV 10/14 to 1/14
Yes
No
Yes
PVR: 2494  256 to 1950  128 dyn s cm5 m2, p Z 0.04 Yes
Bhatia 2003 Epoprostenol þ Sildenafil 5 IPAH 6MWDa: baseline 444.7  111.5 m to 451  114.7, p Z 0.8 No
Functional class 3a: 5 patients to 2 patients No
Kataoka 2004 Epoprostenol þ Sildenafil 1 IPAH mPAP at 12 weekes: baseline 62 mmHg, follow-up 45 mmHg Yes
Kataoka 2005 Epoprostenol þ Sildenafil 20 IPAH Functional class at 12 weeks: stabilization/improvement in 5
patients not responsive to epoprostenol
Yes
mPAP at 12 weeks: 65  15 to 50  13 mmHg, p < 0.0001 Yes
PVR at 12 weeks: 28  12 to 15  8 Wood units, p < 0.0001
Gomberg-Maitland 2005 Treprostinil þ Sildenafil 9 IPAH Functional class: 3 improved, remainder stabilized Trend
Miwa 2007 Beraprost þ Sildenafil 1 SSc-PAH mPAP at 4 weeks: baseline 35 mmHg, 31% reduction at 4 weeks Yes
PVR at 4 weeks: baseline 748 dyn s cm5 m2, 31% reduction at 4 weeks
3MWD at 4 weeks: 15% improvement Yes
Functional class at 4 weeks: III to II Yes
Bendayan 2008 Treprostinil þ Tadalafil 1 SSc-PAH 6MWD at 12 weeks: 155 m to 195 m Yes
Functional class 12 weeks: class IV to III Yes
Onen 2006 Iloprost þ Sildenafil 1 IPAH 6MWD: 440 me580 m Yes
sPAP: 100 to 80 mmHg Yes
Functional class: III to I Yes
Chua 2005 Treprostinil þ Sildenafil 1 IPAH 6MWD at 3 months: improved to 480 m. Yes
Stiebellehner 2003 Epoprostenol þ Sildenafil 2 IPAH 6MWD at 5 months: 428 me498 m Yes
mPAP 60 to 42 mmHg Yes
Ruiz 2006 Epoprostenol/Treprostinil/
Iloprost þ Sildenafil
13 IPAH 6MWD at 1 year: 350  121 to 429  86 m, p Z 0.002 Yes
Functional class at 1 year: 3  0.47 to 2.1  0.8, p Z 0.001 Yes
Randomized trial
Simonneau 2008
PACES Trial
Epoprostenol þ Sildenafil
versus Epoprostenol
212 IPAH
31SSc-PAH
6MWD at 4 months: adjusted treatment difference 28.8 m
(95%CI 13.9, 43.8 m, p < 0.001)
Yes
Time to clinical worsening: better in dual therapy group p Z 0.002,
stratified log rank test)
Yes
mPAP at 4 months: mean change 2.8 mmHg versus 1.1 mmHg,
(adjusted treatment difference 3.8 mmHg, 95% CI -5.6, 2.1 mmHg)
Yes
SF-36 at 4 months: dual therapy had improvements in physical
functioning p Z 0.003, general health p < 0.001, vitality p < 0.001,
social functioning p Z 0.049 and mental health p Z 0.001
Yes
McLaughlin 2010
TRIUMPH -1
Bosentan/Sildenafil þ
Treprostinil/placebo
235 PAH 6MWD at 12 weeks: The Hodges-Lehmann (HL) between treatment median
difference in change from baseline in peak 6MWD was 20 m (p Z 0.0004)
Yes
Sildenafil group: 6MWD at 12 weeks: HL between treatment median difference
in change from baseline in peak 6MWD was 9 m (p Z not significant))
No
IPAH Idiopathic pulmonary arterial hypertension, SSc-PAH Systemic sclerosis associated pulmonary arterial hypertension, 6MWD 6 min walk test distance, PVR Pulmonary vascular
resistance, mPAP mean pulmonary artery pressure, sPAP systolic pulmonary artery pressure.
a Follow-up 117  69 days.
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Table 2 Summary of combination prostaglandin analogue and ERA studies.
Reference Combination Patients Outcome measure Evidence of
benefit
Observational studies
Hoeper 2003 Iloprost/Beraprost þ Bosentan 21 IPAH 6MWD at 12 weeks: baseline
346  106 m, 12-week 404  101 m, 58  43 m change, p < 0.0001
Yes
Functional class at 3 months: 17/21 to 13/21, 71% patients
had improvement of 1 class
Yes
Akagi 2008 Epoprostenol þ Bosentan 8 IPAH sPAP: 80.1  19.3 to 66.8  16.5 mmHg, p < 0.05 Yes
PVR: 9.7  3.1 to 8.1  3.2 Wood units, p < 0.05
Channick 2006 Bosentan þ Treprostinil 6 IPAH
3 SSc-PAH
6MWD at 12 weeks: Baseline 339  86 m, 12 week
406  121 m, 67 m change, p Z 0.01
Yes
mPAP at 12 weeks: 49  10 to 44  12 mmHg, 10% change, p Z 0.04 Yes
PVR at 12 weeks: 9.3  4.9 to 6.9  3.5 Wood units, 26% change, p Z 0.05 No
Functional class: 9/11 patients improve from class III to II Yes
Benza 2008 Treprostinil þ Bosentan 19 PAH mPAP 55.7  15.1 to 47.2  11.6 mmHg, p Z 0.001 Yes
6MWD 332.8  79.6 to 374.2  110.3 m, p Z 0.07 No
Jacobs 2009 Bosentan þ Treprostinil
or Epoprostenol
6 IPAH 6MWD at 4 months: 409  48 to 447  48 m, mean improvement 86 m, p < 0.01 Yes
Functional class improved p Z 0.002 Yes
Provencher 2006 Bosentan þ Epoprostenol
or Iloprost
34 6MWD at 3 months: 310  108 to 347  117 m, p Z 0.031 Yes
mPAP at 3 months: 60  12 to 56  11 mmHg, p Z 0.014 Yes
Launay 2010 Bosentan þ Epoprostenol
or Iloprost
14 SSc-PAH 6MWD at 4 months: 223  111 m, follow-up 191  174 m, p Z 0.85 No
mPAP at 4 months: 55  7 mmHg, follow-up 49  7 mmHg, p Z 0.22 No
PVR at 4 months: 12.9  3.5 mmHg/L/min, follow-up 10.9  3.8 mmHg/L/min, p Z 0.17 No
Randomized trials
Humbert 2004
BREATHE-2
Epoprostenol þ Bosentan
versus Epoprostenol
27 IPAH
5 SSc-PAH
6MWD at 4 months: median change 68 m versus 74 m No
mPAP at 4 months: % change 2.2  3.6 versus 9.0  6.0, p Z 0.3
PVR at 4 months: % change 25.7  7.2 versus 35.2  5.4, p Z 0.3
No
Functional class at 4 months: improvement in 13 patients (59%) versus 5 patients (45%) No
McLaughlin 2006
STEP trial
Bosentan þ Iloprost
versus Bosentan
26 IPAH
29 APAH
6MWD at 3 months: 30 m (p Z 0.001) in dual therapy, 4 m (p Z 0.69)
in monotherapy, between group difference 26 m (p Z 0.69)
Trend
Functional class at 3 months improvement in 11/32 (34%) versus 2/33 (6%), p Z 0.022 Yes
mPAP: change at 3 months 6 mmHg versus þ2 mmHg, p < 0.001 Yes
Time to clinical worsening: Better in dual therapy compared to
monotherapy group p Z 0.02 log rank test
Yes
Hoeper 2006
COMBI trial
Bosentan versus
Bosentan þ Iloprost
40 IPAH 6MWD at 3 months: monotherapy 296 m  79 m to 297  94 m,
(mean change 1  27 m, p Z 0.84); dual therapy 317  74 m to 309  124 m,
(mean change 9 m  100 m, p Z 0.65)
No
Functional class at 3 months: 0.1  0.3 versus 0.1  0.2, p Z 0.64 No
EuroQol at 3 months: 311 versus 7  19, p Z 0.14 No
McLaughlin 2010
TRIUMPH-1
Bosentan/Sildenafil þ
Treprostinil/placebo
235 PAH 6MWD at 12 weeks: The Hodges-Lehmann (HL) between treatment median
difference in change from baseline in peak 6MWD was 20 m (p Z 0.0004)
Yes
Bosentan group: 6MWD at 12 weeks: HL between treatment median difference
in change from baseline in peak 6MWD was 25 m (95% CI 10.2, 40.0) (p Z 0.0002)
Yes
IPAH Idiopathic pulmonary arterial hypertension, SSc-PAH Systemic sclerosis associated pulmonary arterial hypertension, 6MWD 6 min walk test distance, PVR Pulmonary vascular
resistance, mPAP mean pulmonary artery pressure, sPAP systolic pulmonary artery pressure, EuroQol European Quality of Life Instrument, SF-36 The Short Form36 Health Survey.
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Table 3 Summary of ERA and PDE-5 inhibitor studies.
Reference Combination Patients Outcome measure Evidence of benefit
Observational studies
Bhatia 2003 Bosentan þ Sildenafil 3 IPAH 6MWDa: baseline 444.7  111.5 7, p Z 0.8 No
Functional class 3a: 5 patients t No
Minai 2006 Bosentan þ Sildenafil 3 IPAH 6MWD at 3 months: 1160 m, 146 75 m, 1600 m and 645 m Yes
Functional class at 3 months: a roved 1 class Yes
Mathai 2007 Bosentan þ Sildenafil 13 IPAH 12 SSc-PAH Functional class: 5/13 IPAH and proved Trend
6MWD: IPAH 294  104 m to 34 ge 47  77 m, p Z 0.05
SScePAH: No difference
Trend
Hoeper 2004 Bosentan þ add-on Sildenafil 9 IPAH 6MWD at 3 months: 227  80 m p Z 0.007 Yes
Porhownik 2008 Bosentan þ add-on Sildenafil 8 IPAH 2 CTD-PAH 6MWD at 6 months: baseline 33  120, mean
change 62.8 m, p < 0.02
Yes
Functional class at 6 months: 2  0.63 No
Morice 2005 Bosentan þ Sildenafil 1 IPAH sPAP 130 to 50 mmHg Yes
Preston 2005 Bosentan þ Sildenafil 1 IPAH
1 CTD-PAH
Functional class: IPAH patient s ass III; CTD-PAH
improvement from class IV to II
Yes
Sitbon 2010 Bosentan þ add-on Sildenafil 1 IPAH 6MWD at 4 months: 519 me441 No
Functional class at 4 months: b follow-up class III No
Faruqi 2010 Sitaxentan þ Tadalafil 3 IPAH 6MWD at 6 months: baseline 35 m;
follow-up 370, 300, 553
Yes
Randomized trials
Galie 2010
PHIRST trial
Bosentan þ add-on Tadalafil 216 PAH 6MWD at 4 months: placebo adj m 95%
CI -2, 48 m, p Z 0.09
Trend
Functional class at 4 months: 9 d 9.5% worsened
in the tadalafil 40 mg group; 24 d 11.1% worsened
in the placebo group, p > 0.05.
No
Barst 2011
PHIRST trial
Time to clinical worsening 2 pa orsening with
add-on tadalafil versus 5 (11%) bo HR 1.9,
95% CI 0.4, 10.2.
IPAH Idiopathic pulmonary arterial hypertension, SSc-PAH Systemic sclerosis associated pulmonary arterial hype 6 min walk test distance, PVR Pulmonary vascular
resistance, mPAP mean pulmonary artery pressure, sPAP systolic pulmonary artery pressure.
a Follow-up 117  69 days.
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Of the 7 observational studies that reported 6MWD as an
outcome, 4 studies50,52,53,57 reported a treatment benefit
and 1 study51 reported a trend towards a beneficial effect
of dual therapy. Of the 6 studies that reported functional
class, 2 studies50,55 reported a benefit and 1 study51 report
a trend towards improvement in functional class with dual
therapy. One case report described improvement in PAP
with dual therapy.54 No studies reported quality of life.
Randomized trial quality
The randomized trials had quality scores of 4(46), 2(52),
4(38), 5(47), 5(49) and 5(37) indicating largely good quality
studies. Decreased quality scores resulted from lack of
blinding,52 inadequate description of randomization38,52 or
inadequate reporting of withdrawals and dropouts.46
Discussion
Use of dual combination therapy in the management of PAH
is increasingly common. Data from the registry to evaluate
early and long-term PAH disease management (REVEAL
registry) indicates that more than 1000 patients in the
United States were treated with two or more PAH specific
therapies.58 Yet medication payers (governmental programs
and insurance carriers) are reluctant to cover dual combi-
nation therapy due the perceived lack of evidence. This
systematic review synthesizes the current literature eval-
uating the effect of dual therapy with any combination of
ERA, PDE-5 inhibitors or prostaglandin analogues on clini-
cally relevant outcomes in IPAH and SSc-PAH patients. Our
overview of these study findings, provides some insight that
may inform current clinical practice and future research
directions. The overall weight of the literature supports
a beneficial treatment effect of dual therapy compared to
monotherapy on multiple outcome measures. This finding
has face validity as combination therapy is the standard of
care for patients with other sub-optimally managed chronic
diseases including cancer, rheumatoid arthritis and left
ventricular heart disease.59 The finding that a combination
of two medications may be superior to monotherapy also
has biological plausibility as combinations target different
pathways in the pathogenesis of pulmonary hypertension.60
The direction and magnitude of the treatment effect on
each outcome is generally consistent across the observa-
tional studies. However there is discordance between some
observational studies and randomized trials. This discrep-
ancy may be related to variations in the study designs,
particularly administration of dual therapy and patient
selection. Studies varied in the administration of dual
therapy (simultaneous versus sequential), and the order of
administration (prostaglandin analogues before or after
ERA/PDE-5 inhibitor therapy). The observational studies
may also suffer from small patient numbers, reporting bias
and/or overestimation of treatment effect. The differences
in effect between randomized trials and case series could
relate to the observed differences between incident and
prevalent cases of PAH and survival. Randomized trials
generally enrol stable patients (prevalent cases) while caseseries may be evaluating non-stable (excluded from
randomized trials) patients.61 These variations may have
influenced the observed outcomes.
Of the studies that administered dual therapy sequen-
tially, there was variability in how patients were selected
to receive the second agent. In studies where stable
patients were selected/randomized to a second agent or
placebo,30,40,46,48 patients were less likely to derive
a beneficial effect on outcome. Other studies identified
specific subsets of patients to receive the second agent.
Using a ‘step-wise approach’,39,59,62 studies selected
patients who failed to reach pre-defined clinical endpoints
(e.g. using poor prognostic markers15: 6MWD < 380 m and
WHO functional class III or IV). This was done with the
rationale that patients whose condition has stabilized on
monotherapy may derive further improvements or to
suppress side effects resulting from higher doses.40 Using
a ‘rescue approach,’ other studies used pre-defined criteria
to select patients who were deteriorating on mono-
therapy.28,35,36,42,51,54 This is based on the rationale that
patients who are failing may be rescued by add-on
therapy.20 A few studies used a combined approach by
including both types of criteria (e.g. 6MWD < 380 m or
a drop of 50 m on 6MWD).52,53 The weight of evidence in
this review indicates that patients who have add-on
therapy in the face of deterioration on monotherapy
derive greater benefits. This finding is plausible as these
patients are the ones who have the most to gain.
There is insufficient data to determine the optimal dual
combination. There are specific indications for which dual
oral therapy is best suited. First, dual therapy may be
a viable alternative for patients unsuitable for epoproste-
nol. Many patients are not able to use the infusion pump.42
For other patients, the side effects are intolerable. Epo-
prostenol is associated with jaw and leg pain, diarrhoea,
flushing, systemic hypotension, catheter infection or
sepsis.21 Dual oral therapy is also less costly than parenteral
therapy.52 The combination of two oral agents is appealing
due to the ease of administration, cost and tolerability.51
Dual therapy may also provide a bridge to trans-
plantation. Given the effects of transplantation on
a patients’ quality of life,63 and complications limiting
survival after transplantation, any therapy that can
successfully temporize or reduce the need for trans-
plantation is desirable.64 In patients who remain on the
transplant list, combination therapy may increase their
chances of survival to transplantation.
Third, dual oral therapy may facilitate weaning off
invasive continuous intravenous therapy. Combination
bosentan and sildenafil is associated with a higher likeli-
hood of successful transition from epoprostenol than mon-
otherapy.65 This strategy has also been shown to be less
expensive.66 Thus, the aims of dual oral therapy are to
prevent patients from receiving invasive continuous pros-
taglandin analogues, wean off prostaglandin analogues or
delay lung transplantation.
When considering use of dual therapy, issues of safety
(drugedrug interactions, side effects associated with
combination dual therapy), dosing and medication cost
should be considered. The incidence of elevated trans-
aminases is not significantly different in patients taking
sildenafil and bosentan compared to bosentan
Dual therapy in IPAH and SSc-PAH 737monotherapy.64 Bosentan decreases the plasma concen-
tration of sildenafil.67 Sildenafil peak plasma level is
reduced to a third in the presence of chronic bosentan
treatment. An increase in sildenafil dose may be required in
patients using bosentan.67 In another study in healthy
volunteers, sildenafil increased bosentan plasma levels by
50%.64 These issues should be explored further. Plasma
tadalafil concentrations decrease by 40% in healthy volun-
teers taking concomitant bosentan, however this is not
considered a clinically meaningful change.68,69 The PHIRST
trial found no difference in adverse events in the combi-
nation bosentan-tadalafil group compared to the bosentan-
placebo group.69
There were limitations to this study. Our review identi-
fied a large number of observational studies. These obser-
vational studies have small numbers of patients, are
uncontrolled and not blinded to intervention or outcome.
They often suffer from confounding by indication (selection
bias) as treatment is given at the discretion of the treating
physician. Despite their limitations however, these studies
should not be discounted. In the setting of an uncommon
disease and few randomized trials, they provide valuable
information about practice in the real world. Through this
review we have compiled all the observational studies so
that the observed treatment effects can be evaluated
together. In general, the direction and the magnitude of
the observed treatment effects are consistent, and indicate
that a signal of effectiveness is present. Due to the
heterogeneity of patient groups, follow-up time, variations
in outcome measurement and variations in the dual
combinations, a meta-analysis of all the studies was not
appropriate.70 Others have published reviews (review,71
systematic review,72 guidelines,73 expert consensus docu-
ment,74 evidence-based update3) relating to combination
therapy in PAH. Another consideration is that our search
was limited to the adult population. As such, our results
may not be generalizable to the paediatric population.
The strength of this systematic review is that it reports
a greater breadth of evidence (that was excluded by the
others) to support our recommendations. This systematic
review supplements the work already done in this area, and
independently validates their findings. Our findings and
recommendations are consistent with those of the
evidence-based treatment algorithm from the 4th World
Pulmonary Hypertension Symposium,3 the Canadian Agency
for Drugs and Technologies in Health,72 the American
College of Cardiology Foundation and American Heart
Association Expert Consensus Document on Pulmonary
Hypertension,74 and treatment guidelines of the European
Society of Cardiology and the European Respiratory
Society.73Conclusion
The results of this systematic review suggests that dual
combination therapy improves multiple clinically relevant
outcomes in IPAH and SSc-PAH patients, particularly those
who fail to meet pre-defined clinical end-points or are
deteriorating on monotherapy. Further research is needed
to identify the optimal dual combination, timing of initia-
tion, and criteria for patient selection. Until evidence isavailable, we support the recommendation that dual
combinations should be initiated by experts in the field who
have substantial experience in dealing with PAH patients,
and have access to the resources of a pulmonary hyper-
tension center of excellence.50,73,75 The decision for
appropriate dual combination should be made on an indi-
vidual basis.73 Ideally, patients should participate in clinical
trials so that the optimal treatment strategy can be
identified.73
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